NIH-funded research Sbir 2 grant

Modular bioluminescence imaging platform with a new multi-aperture method

Official title: A modular bioluminescence imaging platform using a novel multi-aperture method

Funded at In Vivo Analytics, INC. · NIH-11384484 · Data updated 2026-11-12

A new imaging platform using multiple views and a unique mirror system aims to greatly improve live tracking of disease processes in small animal models.

Quick facts

Grant typeSbir 2 grant
Study typeNIH-funded research
Funding institutionIn Vivo Analytics, INC.
NIH-funded
Lab location1 site (New York, United States)
Project startAugust 2, 2024
Project endJuly 31, 2027
Funding year2026
Award (this year)$907,050
NIH project number5R44MH140129-03
Project IDNIH-11384484 on NIH RePORTER

Who could benefit from this research

Could help

Ideal candidates are researchers and labs using small animal models to study human diseases where non-invasive imaging informs treatment development.

Less likely to help

Direct patient participation is not part of this preclinical imaging grant, so patients would not be enrolled in this study.

What this research studies

This grant supports developing an advanced bioluminescence imaging system that works better for detecting signals from deep or weak targets in small animals. The project introduces a modular imaging platform with a concentric mirror and stray-light collimator to enable multi-view, 3D tomography and better anatomical alignment. It usesBody-Conforming Animal Molds and Organ Probability Maps to provide instant anatomical context and automated, reproducible measurements. The goal is to make bioluminescence imaging more sensitive, accurate, and user-friendly for preclinical disease research.

Why it matters

Potential benefit: If successful, patients could benefit indirectly through faster, more reliable preclinical research that informs safer and more effective therapies.

How similar studies have gone: Previous bioluminescence imaging work has shown value, but this project emphasizes a novel multi-aperture approach for improved sensitivity and 3D localization.

Where this research is happening

  • In Vivo Analytics, INC.
    New York, United States
    Active

Researchers

  • Principal investigator: Klose, Alexander D. — In Vivo Analytics, INC.
  • Study coordinator: Klose, Alexander D.

Related research

Other NIH-funded projects on the same topics.

  • Automated PET tools to map how tracers spread in tumors

    This project builds a cloud tool that automatically finds organs and measures PET tracer uptake in animal cancer scans to speed imaging and drug research.

    NIH research In Vivo Analytics, INC. · New York, United States · NIH-11195063

  • A new imaging platform to enhance bioluminescence imaging for studying diseases in small animals

    This study is working on a new imaging tool that helps scientists see what's happening inside small animals with diseases like cancer, making it easier to understand and study these conditions better.

    NIH research In Vivo Analytics, INC. · New York, United States · NIH-11007824

  • Automatic analysis of PET imaging for cancer treatment

    This study is working on a new online tool that helps doctors quickly and accurately analyze PET scans to better understand how cancer treatments are working in the body, which could lead to improved care for patients like you.

    NIH research In Vivo Analytics, INC. · New York, United States · NIH-10917862

About this research

  1. This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
  2. Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
  3. For full project details, budget, and progress reports, visit the official NIH RePORTER page.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.